We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.20 | 0.49% | 41.11 | 41.3125 | 40.87 | 40.95 | 2,730,464 | 01:00:00 |
From Apr 2019 to Apr 2024
By Ian Walker
LONDON--Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) said Wednesday a phase III study of mepolizumab has met all major targets in patients with eosinophilic granulomatosis with polyangiitis, a rare disease characterized by inflammation in the walls of small blood vessels.
The key goal of treatment is to induce and maintain remission while reducing the use of corticosteroids and other immunosuppressive therapies, Glaxo said.
It plans to use the results to support regulatory applications, which are expected in 2017.
Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
November 23, 2016 02:41 ET (07:41 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
